Do you routinely offer ovarian suppression in addition to aromatase-inhibitor in premenopausal patients under 50 with an intermediate oncotype score (11-25)?

In the setting of the recent TailorRx data, would these patients be considered more high risk?

Answer from: Medical Oncologist at Academic Institution

The TAILORx trial showed that endocrine therapy was noninferior to chemoendocrine therapy in the primary endpoint of invasive-disease free survival among patients who had a recurrence score between 11-25. However, an exploratory subgroup analysis showed a significant interaction between chemotherapy...

Comments

at BayCare Medical Group
Would you offer OFS for patients who underwent che...

Medical Oncologist at Los Angeles VA Medical Center
Dr. @Logan Corey, we have a few related threads, b...

Please select the option that best describes you:

Do you routinely offer ovarian suppression in addition to aromatase-inhibitor in premenopausal patients under 50 with an intermediate oncotype score (11-25)?

Related Questions